Neuro-oncology, skull-base anatomy and tissue diagnosis
Neuro-oncological assessment separates anatomical localization, imaging pattern, tissue diagnosis, molecular classification and treatment planning. An enhancing mass can suggest a differential without proving one molecular entity. A diffuse adult glioma classification may require specific genetic observations that cannot be inferred solely from a ring-enhancing image or a familiar histological pattern. A practice question must supply the defining evidence or explicitly ask which molecular feature is required, rather than silently treating probable appearance as a complete modern diagnosis.
Oligodendroglioma requires the relevant IDH mutation and whole-arm 1p and 19q codeletion in the current integrated framework. A biomarker such as MGMT promoter methylation has a different purpose from a defining lineage marker. It can inform a treatment-response discussion in the relevant glioblastoma context but is not a guarantee for every individual. Temozolomide-related methylation injury should not be confused with a generic DNA-crosslink mechanism. Tumor stage, grade, extent of resection, patient function and response each provide separate information.
Meningioma assessment combines location, symptoms, pathology, molecular findings where relevant and treatment effects. A Simpson resection grade describes what was removed or treated surgically, not the same thing as a WHO pathological grade. Resection of the attachment and involved bone differs from coagulation alone. A small observed lesion and a large symptomatic mass require different discussions. Skull-base work also involves the cranial nerves, vessels and compartments; knowing a foraminal nerve group or cavernous-sinus relationship supports localization without demonstrating ability to execute an approach.
Sellar and parasellar lesions require endocrine as well as anatomical assessment. A hormone-secreting lesion may have a medical-first pathway, while visual compromise, apoplexy, atypical findings or resistance can change the situation. A prolactin result can be affected by assay and clinical factors, so it should not be detached from the presentation and imaging. Craniopharyngioma, pituitary lesions and meningioma are not interchangeable diagnoses. Protecting hypothalamic, visual and endocrine function is part of planning, not an optional afterthought to maximal visible removal.
For metastases and other tumors, intervention depends on symptoms, location, disease burden, systemic status, pathology and patient goals. Local resection, focused radiation, systemic treatment and observation are not chosen from the lesion count alone. Restricted diffusion or perfusion changes can support a differential or response assessment without being infallible. Suspected primary CNS lymphoma raises particular diagnostic issues around prior treatment and tissue yield, but physiological emergencies still require individual judgment. Do not import a fixed chemotherapy or radiation schedule as a universal current rule. Written cases support interpretation and tradeoffs rather than practical skull-base or oncological competence.